Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene's Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer

In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumors Phase 3 ELAINE-3 study is currently investigating lasofoxifene as a potential therapy [...]